Author

Fernando Magro

Bringing light into new treatment targets: the role of histology and molecular healing in UC (Eli Lilly and Company) (Complete Session)
Bringing light into new treatment targets: the role of histology and molecular healing in UC (Eli Lilly and Company) (Complete Session)

Fernando Magro  et al.

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Fernando Magro  et al.

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS
EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Summary: Disease activity in IBD - When and how hard to look for it?
Summary: Disease activity in IBD - When and how hard to look for it?

Fernando Magro

ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

Fernando Magro  et al.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

Fernando Magro  et al.

Opportunistic infections in IBD
Opportunistic infections in IBD

Fernando Magro

COVID-19: Lessons learned
COVID-19: Lessons learned

Fernando Magro

ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY
ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY

Fernando Magro  et al.

PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY
PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY

EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS
EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS

Fernando Magro  et al.

ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY
ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS
EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Fernando Magro  et al.

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Gathering intelligence to improve long-term outcomes in ulcerative colitis: new evidence (Takeda) (Complete Session)
Gathering intelligence to improve long-term outcomes in ulcerative colitis: new evidence (Takeda) (Complete Session)

Fernando Magro  et al.

The impact of COVID-19 pandemic in Gastroenterology: focus on IBD
The impact of COVID-19 pandemic in Gastroenterology: focus on IBD

Fernando Magro  et al.

PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY
PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY

Fernando Magro  et al.

European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease
European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease

Fernando Magro  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

Fernando Magro  et al.

HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Fernando Magro  et al.

Item 1 - 20 / 35
1
2